Targeting the metabolic vulnerability of drug-resistant B-cell lymphoma with the MPC inhibitor MITO-21

• Unité de recherche: INNOSUISSE
• Numéro de projet: 139.810 INNO-LS
• Titre du projet anglais: Targeting the metabolic vulnerability of drug-resistant B-cell lymphoma with the MPC inhibitor MITO-21

Mots-clé (Anglais)

Life sciences, Biotechnology and processing

Résumé des résultats (Abstract) (Anglais)

MPC Therapeutics SA and the Institute of Oncology Research (IOR) test whether MITO-21, a mitochondrial pyruvate carrier inhibitor, can target drug-resistant B-cell lymphoma and resensitize it to existing treatments ? a new metabolic approach.